Pharmaceutical

AusperBio secures funding to advance AHB-137 for CHB

AusperBio has raised $37m in a Series A financing round to progress the clinical development of AHB-137 for chronic hepatitis B (CHB).

Jul 16, 2024 - 04:00
AusperBio secures funding to advance AHB-137 for CHB
AusperBio has raised $37m in a Series A financing round to progress the clinical development of AHB-137 for chronic hepatitis B (CHB).
Read the original article

Tags:

Previous Article

Exploring Melbourne’s booming life sciences sector

Next Article

Mabwell’s 9MW2821 gains FDA fast track status for breast cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Addex spinoff Neurosterix debuts with $63m for developing neurological therapies

Addex spinoff Neurosterix debuts with $63m for developi...

Apr 5, 2024

STAT+: Vinod Khosla predicts AI doctors could be here sooner than you think

STAT+: Vinod Khosla predicts AI doctors could be here s...

May 3, 2023

STAT+: Pharmalittle: We’re reading about White House eyeing PBMs, Pfizer CEO’s frustrations, and more

STAT+: Pharmalittle: We’re reading about White House ey...

Feb 29, 2024